From the AGA Journals

Study eyed natural history of branch-duct intraductal papillary mucinous neoplasms

 

Key clinical point: Tailor the surveillance of BD-IPMNs based on initial diameter and the presence or absence of high-risk features.

Major finding: Median annual growth rate was 0.8 mm.

Data source: A retrospective study of 1,369 patients with BD-IPMNs.

Disclosures: The study was funded by a grant from the Korean Health Technology R&D Project of the Ministry of Health and Welfare, Republic of Korea. The investigators reported having no conflicts of interest.

Source: Han Y et al. Gastroenterology. 2018. doi: 10.1053/j.gastro.2017.10.013.

View on the News

Questions linger despite this important step
Aatur D. Singhi, MD, PhD

The appropriate management of branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs), a precursor cystic lesion to pancreatic cancer, has been a controversial issue since their initial description in 1982. Current national and international guidelines are primarily based on surgical series with potential selection bias and on observational studies with short surveillance periods. Consequently, there is limited information on the natural history and, more importantly, the malignant potential of BD-IPMNs.
The study by Youngmin Han and colleagues represents a comprehensive analysis of over 1,000 patients, each with at least 3 years of follow-up for a suspected BD-IPMN. In addition, the authors identified an optimal screening method for patients based on cyst size. Their data largely validates prior reports and will undoubtedly serve as the basis for future pancreatic cyst guidelines.


However, as the authors note, limitations of their study include its retrospective design and validation of their screening protocol. Moreover, several lingering questions remain for patients with BD-IPMNs: What is the best method of measuring a BD-IPMN (for example, CT, MRI, or endoscopic ultrasound)? How long should surveillance continue? And what is the role for cytopathology and ancillary studies, such as carcinoembryonic antigen testing, molecular testing, and testing for other pancreatic cyst biomarkers? At the risk of enouncing a cliché, “further studies are needed” to identify an optimal treatment algorithm and, considering the increasingly frequent detection of pancreatic cysts, a cost-effective approach to the evaluation of patients with BD-IPMNs.

Aatur D. Singhi, MD, PhD, is in the division of anatomic pathology in the department of pathology at the University of Pittsburgh Medical Center. He has no conflicts of interest.


 

FROM GASTROENTEROLOGY

Branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) grew at a median annual rate of 0.8 mm in a retrospective study of 1,369 patients.

Based on their findings, the researchers recommended surgery for young, fit, asymptomatic patients who have BD-IPMNs with a diameter of least 30 mm or with thickened cyst walls or those who have a main pancreatic duct measuring 5-9 mm. Surgery also should be considered when patients have lymphadenopathy, high tumor marker levels, or an abrupt change in pancreatic duct caliber with distal pancreatic atrophy or a rapidly growing cyst, they said.

For asymptomatic patients whose cysts are under 10 mm and who do not have worrisome features, they recommended follow-up with CT or MRI at 6 months and then every 2 years after that. Cysts of 10-20 mm should be imaged at 6 months, at 12 months, and then every 1.5-2 years after that, they said. Patients with cyst diameters greater than 20 mm “should undergo MRI or CT or EUS [endoscopic ultrasound] every 6 months for 1 year and then annually thereafter, until the cyst size and features become stable,” they added. Patients whose cysts have a diameter of 30 mm or greater “should be closely monitored with MRI or CT or EUS every 6 months. Surgical resection can be considered in younger patients or those with other combined worrisome features.”

To characterize the natural history of BD-IPMN, the investigators evaluated clinical and imaging data collected between 2001 and 2016 from patients with classical features of BD-IPMN. Each patient included in the study provided 3 or more years of CT, MRI, EUS, and endoscopic retrograde cholangiopancreatography data. The researchers used regression models to estimate changes in sizes of cysts and main pancreatic ducts.

Median follow-up time was 61 months (range, 36-189 months). Cyst diameter averaged 12.8 mm (standard deviation, 6.5 mm) at baseline and 17 mm (SD, 9.2 mm) at final measurement. Larger baseline diameter was associated with faster growth (P = .046): Cysts measuring less than 10 mm at baseline grew at a median annual rate of 0.8 mm (SD, 1.1 mm), while those measuring at least 30 mm grew at a median annual rate of 1.2 mm (SD, 2.1 mm).

Worrisome features were present in 59 patients at baseline and emerged in another 150 patients during follow-up. At baseline, only 2.3% of cysts exceeded 30 mm in diameter, but 8.0% did at final measurement. Cyst wall thickening was found in 0.5% of patients at baseline and 3.7% of patients at final measurement. Main pancreatic ducts measured 5-9 mm in 1.9% of patients at baseline and in 5.6% of patients at final measurement. Additionally, the prevalence of mural nodules rose from 0.4% at baseline to 3.1% at final measurement.

Main pancreatic ducts averaged 1.8 mm (SD, 1.0 mm) at baseline and 2.4 mm (SD, 1.8 mm) at final measurement. Compared with the values seen with smaller cysts, larger baseline cyst diameter correlated significantly with larger main pancreatic ducts, more cases of cyst wall thickening, and more cases with mural nodules (P less than .001 for all comparisons).

The study was funded by a grant from Korean Health Technology R&D Project of Ministry of Health and Welfare, Republic of Korea. The investigators reported having no conflicts of interest.

SOURCE: Han Y et al. Gastroenterology. 2018. doi: 10.1053/j.gastro.2017.10.013.

Next Article: